ImmunityBio (IBRX) Common Equity (2013 - 2026)
ImmunityBio (IBRX) reported Common Equity of -$869.1 million for Q1 2026, down 47.19% year-over-year from -$1.6 billion in Q1 2025, and down 73.97% on a QoQ basis from -$499.6 million in Q4 2025.
ImmunityBio (IBRX) has 14 years of Common Equity data on file, last reported at -$869.1 million in Q1 2026.
- Quarterly Common Equity fell 47.19% year-over-year to -$869.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$869.1 million (down 47.19% YoY) and the FY2025 annual result came in at -$499.6 million, down 2.34% from the prior year.
- Common Equity fell to -$869.1 million in Q1 2026 per IBRX's latest filing, from -$499.6 million in the prior quarter.
- Across five years, Common Equity topped out at -$337.6 million in Q1 2022 and bottomed at -$869.1 million in Q1 2026.
- The 5-year median for Common Equity is -$531.7 million (2023), against an average of -$557.9 million.
- The widest annual swing landed in 2022, when Common Equity sank 166.09%; it then grew 29.66% in 2025.
- Tracing IBRX's Common Equity over 5 years: stood at -$449.8 million in 2022, then slumped by 30.26% to -$585.9 million in 2023, then advanced by 16.69% to -$488.1 million in 2024, then retreated by 2.34% to -$499.6 million in 2025, then slumped by 73.97% to -$869.1 million in 2026.
- Per Business Quant, the three latest IBRX Common Equity figures stand at -$869.1 million (Q1 2026), -$499.6 million (Q4 2025), and -$523.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -869.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -869.13 Mn |
| Dec 31, 2025 | -499.57 Mn |
| Sep 30, 2025 | -523.41 Mn |
| Jun 30, 2025 | -569.82 Mn |
| Mar 31, 2025 | -590.48 Mn |
| Dec 31, 2024 | -488.13 Mn |
| Sep 30, 2024 | -744.16 Mn |
| Jun 30, 2024 | -697.38 Mn |
| Mar 31, 2024 | -690.98 Mn |
| Dec 31, 2023 | -585.94 Mn |
| Sep 30, 2023 | -410.65 Mn |
| Jun 30, 2023 | -645.18 Mn |
| Mar 31, 2023 | -531.72 Mn |
| Dec 31, 2022 | -449.82 Mn |
| Sep 30, 2022 | -429.08 Mn |
| Jun 30, 2022 | -421.97 Mn |
| Mar 31, 2022 | -337.56 Mn |
| Dec 31, 2021 | -243.91 Mn |
| Sep 30, 2021 | -189.94 Mn |
| Jun 30, 2021 | -158.59 Mn |
| Mar 31, 2021 | -185.34 Mn |
| Dec 31, 2020 | -118.49 Mn |
| Sep 30, 2020 | -51.07 Mn |
| Jun 30, 2020 | 14.38 Mn |
| Mar 31, 2020 | -20.70 Mn |
| Dec 31, 2019 | 16.33 Mn |
| Sep 30, 2019 | 135.96 Mn |
| Jun 30, 2019 | 151.27 Mn |
| Mar 31, 2019 | 167.81 Mn |
| Dec 31, 2018 | 81.94 Mn |
| Sep 30, 2018 | 162.09 Mn |
| Jun 30, 2018 | 181.63 Mn |
| Mar 31, 2018 | 200.36 Mn |
| Dec 31, 2017 | 218.84 Mn |
| Sep 30, 2017 | 237.70 Mn |
| Jun 30, 2017 | 252.92 Mn |
| Mar 31, 2017 | 278.37 Mn |
| Dec 31, 2016 | 293.42 Mn |
| Sep 30, 2016 | 310.89 Mn |
| Jun 30, 2016 | 327.36 Mn |
| Mar 31, 2016 | 344.50 Mn |
| Dec 31, 2015 | 356.00 Mn |
| Sep 30, 2015 | 362.93 Mn |
| Jun 30, 2015 | 126.52 Mn |
| Dec 31, 2014 | 57.59 Mn |
| Dec 31, 2013 | -3.76 Mn |